OncoMatch/Clinical Trials/NCT06235437
Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141
Is NCT06235437 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ASD141 for metastatic solid tumor.
Treatment: ASD141 — This is a Phase I study designed to evaluate if ASD141 is safe, tolerable, and efficacious in participants with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy, investigational or approved cancer therapy (e.g., chemotherapy, biologics, hormone)
Exception: within 2 weeks or 5 halflives (whichever is shorter) prior to the first dose of study treatment
Has had curative radiotherapy, investigational or approved cancer therapy (e.g., chemotherapy, biologics, hormone [e.g., tamoxifen, leuprolide]) within 2 weeks or 5 halflives (whichever is shorter) prior to the first dose of study treatment.
Cannot have received: investigational device
Exception: within 4 weeks prior to the first dose of study treatment
Has used an investigational device or has had major surgery within 4 weeks prior to the first dose of study treatment.
Cannot have received: CD11b inhibitor
Has received previous treatment with another agent targeting the CD11b receptor.
Lab requirements
Blood counts
Neutrophil Count (ANC) ≥ 1,500 /µL; Platelets ≥ 100,000 /µL; Hemoglobin ≥ 9 g/dL
Kidney function
estimated GFR (non-indexed) ≥ 50 mL/min
Liver function
Serum total bilirubin ≤ 1.5X ULN OR Direct bilirubin ≤ 1.5X ULN for subjects with total bilirubin levels > 1.5 ULN; ≤ 3X ULN for subjects with hepatoma or Gilbert's disease; AST and ALT ≤ 2.5X ULN OR ≤ 5X ULN for subjects with active liver metastases and primary hepatoma
Cardiac function
QTcF < 480 msec; INR ≤ 1.5X ULN; aPTT ≤ 1.5X ULN
adequate organ function as indicated by the following laboratory values. Hematological Neutrophil Count (ANC) ≥ 1,500 /µL (mm3) Platelets ≥ 100,000 /µL (mm3) Hemoglobin ≥ 9 g/dL Renal estimated GFR (non-indexed)* ≥ 50 mL/min Hepatic Serum total bilirubin ≤ 1.5X ULN OR Direct bilirubin ≤ 1.5X ULN for subjects with total bilirubin levels > 1.5 ULN; ≤ 3X ULN for subjects with hepatoma or Gilbert's disease AST and ALT ≤ 2.5X ULN OR ≤ 5X ULN for subjects with active liver metastases and primary hepatoma Coagulation International normalized ratio (INR) ≤ 1.5X ULN Activated partial thromboplastin time (aPTT) ≤ 1.5X ULN; QTcF < 480 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06235437 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, investigational or approved cancer therapy (e.g., chemotherapy, biologics, hormone), investigational device, CD11b inhibitor disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify